SCHEMBL1532832

SCHEMBL1532832

CC1(C(=O)O)CNCCN1C(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 1/20 0.48
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
GAA P10253 2/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 1/20 0.41
P2RX4 Q99571 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29174999 0.91 HTR2C (0.47) HTR2CKMT2AMEN1NPSR1NPC1
SCHEMBL15000800 0.87 HTR2C (0.50) HTR2CKMT2AMEN1NPSR1NPC1
SCHEMBL31084552 0.83 HTR2C (0.48) HTR2CKMT2AMEN1NPSR1NPC1
SCHEMBL630773 0.83 MEN1 (0.49) HTR2CKMT2AMEN1NPSR1NPC1
SCHEMBL7245273 0.83 MEN1 (0.49) HTR2CKMT2AMEN1NPSR1NPC1
SCHEMBL29174956 0.82 HTR2C (0.42) HTR2C
SCHEMBL27254036 0.82 HTR2C (0.47) HTR2CKMT2AMEN1NPSR1NPC1
Trifluoroacetic Acid SCHEMBL15019736 0.81 HTR2C (0.44) HTR2CKMT2AMEN1NPSR1NPC1
Pyridine SCHEMBL28216266 0.81 HTR2C (0.44) HTR2CKMT2AMEN1NPSR1NPC1
Hydrochloric Acid SCHEMBL26983226 0.81 HTR2C (0.46) HTR2CKMT2AMEN1NPSR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117430633-A Small molecular compound for treating ischemic stroke and preparation method and application thereof 上海市第六人民医院 2024-01-23 CN claimed
US-20250120988-A1 SMALL MOLECULE COMPOUND FOR TREATING ISCHEMIC STROKE, ITS PREPARATION METHOD, AND APPLICATION SHANGHAI SIXTH PEOPLE'S HOSPITAL (CN) 2025-04-17 US disclosed
CN-117430633-A Small molecular compound for treating ischemic stroke and preparation method and application thereof 上海市第六人民医院 2024-01-23 CN disclosed
EP-2607362-B1 Piperidine and piperazine carboxylates as FAAH inhibitors ASTELLAS PHARMA INC (JP) 2014-12-31 EP disclosed
EP-1849773-B1 Piperazine derivatives for the treatment of urinary incontinence and pain ASTELLAS PHARMA INC (JP) 2013-10-16 EP disclosed
EP-2607362-A1 Piperidine and piperazine carboxylates as FAAH inhibitors Astellas Pharma Inc. (JP) 2013-06-26 EP disclosed
US-7919494-B2 Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound ASTELLAS PHARMA, INC. (JP) 2011-04-05 US disclosed
US-7919495-B2 Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound ASTELLAS PHARMA, INC. (JP) 2011-04-05 US disclosed
US-7915261-B2 Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound ASTELLAS PHARMA, INC. (JP) 2011-03-29 US disclosed
US-20100009972-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound ASTELLAS PHARMA INC. (JP) 2010-01-14 US disclosed
US-20100009971-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound ASTELLAS PHARMA INC. (JP) 2010-01-14 US disclosed
US-20080306046-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative FMC CORPORATION (US) 2008-12-11 US disclosed
EP-1849773-A1 PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE Astellas Pharma Inc. (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250120988-A1 SMALL MOLECULE COMPOUND FOR TREATING ISCHEMIC STROKE, ITS PREPARATION METHOD, AND APPLICATION GRIN2B, GRIN2A, GRIN2C HTR2C 273/4885KMT2A 666/4885MEN1 3915/4885
US-20080306046-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative FAAH, FAAH2, APEH HTR2C 1125/4885KMT2A 2467/4885MEN1 4843/4885
US-20100009972-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound FAAH, FAAH2, CNR2 HTR2C 446/4885KMT2A 2469/4885MEN1 4731/4885
US-20100009971-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound FAAH, FAAH2, CNR1 HTR2C 467/4885KMT2A 2502/4885MEN1 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.